Physicians' Academy for Cardiovascular Education

kanweg

July 4, 2016

10 minute education • 28-6-2016

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

ESC HF 2016 David Fitchett discusses the results of the EMPA-REG OUTCOME trial: the first published trial evaluating CV endpoints with an SGLT2 inhibitor.

Meeting report • 4-7-2016 • Florence, Italy - 23 May 2016

Optimizing RAAS inhibition in Heart Failure

ESC HF 2016 Optimizing RAAS inhibition in Heart Failure: Novel treatment considerations for the management of hyperkalemia ESC Heart Failure Congress, Florence, Italy - May 23.

Meeting report • 4-7-2016 • ESC Heart Failure Congress, Florence, Italy - May 21

Diabetes & Heart failure

ESC HF 2016  Diabetes & Heart failure: Evaluating novel strategies to address outcomes ESC Heart Failure Congress, Florence, Italy - May 21.

10 minute education • 28-6-2016

Current treatment of Diabetes in Heart Failure

ESC HF 2016 Patients with both HF and diabetes have poor prognosis. Adriaan Voors reviews which currently available therapies provide benefit and which may increase risk in these patients.

10 minute education • 28-6-2016

RAAS inhibition in heart failure: Corner stone of therapy & potassium homeostasis

ESC HF 2016 Many HF patients are treated suboptimally, with hyperkalemia being one of the underlying reasons. Faiez Zannad considers this clinical scenario, its consequences and how it can be managed.

10 minute education • 28-6-2016

Hyperkalemia: Novel treatment strategies to manage potassium levels in heart failure

ESC HF 2016 Conventional therapies to treat hyperkalemia are associated with clinical complications. Peter van der Meer discusses the mechanism and efficacy and safety results of two new therapeutic options that lower potassium levels: patiromer and ZS-9.

10 minute education • 28-6-2016

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

ESC HF 2016 The results of the EMPA-REG outcome trial have changed views on how SGLT2 inhibition may yield benefit. Naveed Sattar describes the emerging mechanistic concept based on the latest trial data.

10 minute education • 28-6-2016

The future of HF management: How does potassium binding fit within pharmacological treatment of heart failure?

ESC HF 2016 Kenneth Dickstein considers the increase in potassium levels that arise as a consequence of blocking the renin-angiotensin system. Hyperkalemia is often a reason for not following guideline-recommended therapy, which underlines the need for novel potassium-lowering therapy.

News • 24-5-2016

One in four patients develop heart failure within four years of first heart attack

ESC HF 2016 Data from the UK based CALIBER programme reveal that risk factors include older age, socioeconomic deprivation, and diabetes.

News • 23-5-2016

No benefit of direct renin inhibitor in heart failure patients with diabetes

ESC HF 2016 Subgroup analysis of ATMOSPHERE fails to show a benefit of aliskiren as compared with enalapril in HF patients with diabetes. Combination therapy is associated with excess adverse events.

News • 23-5-2016

Flu jab associated with fewer hospitalisations in patients with heart failure

ESC HF 2016 Study ends controversy over influenza vaccination in heart failure patients and provides more robust evidence for current recommendations.

News • 23-5-2016

Exercise associated with longer life in patients with heart failure

ESC HF 2016 Individual patient data meta-analysis ExTraMATCH II shows that all patients benefited regardless of heart failure severity, age and gender.

News • 21-5-2016

Ten commandments on optimal management of heart failure

ESC HF 2016 At the presentation of the new ESC Heart Failure Guidelines, Professor Ponikowski, Chairperson of the guidelines Task Force, summarised the guidelines as ten commandments.

News • 21-5-2016

New ESC heart failure guidelines include distinct mid-range LVEF category

ESC HF 2016 A new ESC HF guideline was presented at the ESC Heart Failure Congress in Florence, and includes a new definition of HF, and updated treatment algorithms for chronic and acute HF.

3 minute education • 21-5-2016, ESC HF 2016, Florence, Italy, Adriaan Voors (Groningen, The Netherlands)

New 2016 ESC Heart Failure Guidelines

ESC HF 2016 Adriaan Voors, ESC Heart Failure Guideline Task Force Co-Chairman summarises the most important changes in the 2016 guideline presented in Florence at the ESC Heart Failure Congress today, as compared with the 2012 guidelines.

Slides • 28-10-2015

Sugar vs Fat: is treatment of dyslipidaemia relevant for diabetes?

Presentation prepared and held by Naveed Sattar (University of Glasgow, United Kingdom) in an Xchange Session during ISA2015 (Amsterdam, The Netherlands, May 23-26 2015).

Meeting report • 29-5-2015 • An Xchange session held at ISA2015

Diabetes and its novel interventions

Watch and download the presentations of this ISA2015 session on the latest insights into diabetes and management of comorbidities.  

Literature • 10-11-2014 • Welsh P et al., Diabetologia. 2014

Insulin resistance does not seem to increase CVD risk in elderly without diabetes

Insulin resistance and hyperinsulinaemia predispose to diabetes in the elderly, but do not increase the risk of mortality or CVD events.

News • 13-10-2014

An impression of the controversies and hot issues discussed at the PACE SNAPSHOT meeting

This meeting provided a comprehensive update of the latest developments and challenges in the managament of CVD. What follows is an impression of what was discussed.